report_lead_image_with_gradient.png
Q2 2025

Healthtech Public Comp Sheet and Valuation Guide

Download this Report
To download this report, please complete the form below

Fill out the form to download a preview of this report. The full Excel data pack is available through the PitchBook Platform.

Hinge Health and Omada signal cautious reopening of healthtech IPO window

After years of dormancy in digital health exits, Q2 brought a shift with Hinge Health and Omada Health making their public debuts. These high-profile listings signal a cautious reopening of the public markets for VC-backed healthtech platforms, and the success of these IPOs is likely to shape sentiment for the sector’s next wave of exits. Hinge’s shares surged nearly 62% by quarter’s end despite a listing below its last private round, while Omada’s share price slipped through the quarter.

Healthtech equities overall navigated turbulent macro conditions better than expected, with virtual care and remote patient monitoring stocks outperforming major indexes thanks to double-digit gains from Modivcare and LifeMD.

Our Q2 2025 Healthtech Public Comp Sheet and Valuation Guide tracks metrics for key publicly traded companies that include stock performance, changes in valuation, historical valuations, revenue growth, EBITDA growth, and EBITDA margins. It is constructed using the PitchBook Excel plugin available to subscribers.


Table of contents
Key takeaways 2
Stock returns 4
Valuations 5
Revenue 6
EBITDA 8